Skip to main content

Advertisement

Figure 2 | Malaria Journal

Figure 2

From: Monitoring antimalarial safety and tolerability in clinical trials: A case study from Uganda

Figure 2

Clinical treatment failure and analysis of adverse events. The proportion of participants experiencing an adverse event of weakness in the five studies comparing chloroquine + sulphadoxine-pyrimethamine (CQ+SP), amodiaquine + sulphadoxine-pyrimethamine (AQ+SP), and artesunate + amodiaquine (AS+AQ) is shown for all participants, and after excluding clinical treatment failures.

Back to article page